Fibrin Fibrinogen Degradation Products
"Fibrin Fibrinogen Degradation Products" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
| Descriptor ID |
D005338
|
| MeSH Number(s) |
D12.776.124.270.300 D12.776.811.300.290
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fibrin Fibrinogen Degradation Products".
Below are MeSH descriptors whose meaning is more specific than "Fibrin Fibrinogen Degradation Products".
This graph shows the total number of publications written about "Fibrin Fibrinogen Degradation Products" by people in this website by year, and whether "Fibrin Fibrinogen Degradation Products" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2002 | 0 | 2 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 3 | 1 | 4 |
| 2018 | 1 | 1 | 2 |
| 2020 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fibrin Fibrinogen Degradation Products" by people in Profiles.
-
Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic: A Position Paper From the National PERT Consortium. Chest. 2020 12; 158(6):2590-2601.
-
How to Build the Plane While Flying: VTE/PE Thromboprophylaxis Clinical Guidelines for COVID-19 Patients. Disaster Med Public Health Prep. 2020 Jun; 14(3):391-405.
-
Age-Adjusted D-dimer Cutoffs: A Warning From the Laboratory. Ann Emerg Med. 2020 06; 75(6):783-784.
-
Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am J Hematol. 2019 01; 94(1):21-28.
-
Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Institute/Food and Drug Administration guideline: results of a multicenter management study. Blood Coagul Fibrinolysis. 2018 Sep; 29(6):562-566.
-
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. Thromb Haemost. 2017 12; 117(12):2389-2395.
-
The role of D-dimer testing in clinical hematology and oncology. Clin Adv Hematol Oncol. 2017 Aug; 15(8):580-583.
-
Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study. Blood Coagul Fibrinolysis. 2017 Apr; 28(3):254-260.
-
D-Dimer Use and Pulmonary Embolism Diagnosis in Emergency Units: Why Is There Such a Difference in Pulmonary Embolism Prevalence between the United States of America and Countries Outside USA? PLoS One. 2017; 12(1):e0169268.
-
Issues Surrounding Age-Adjusted d-Dimer Cutoffs That Practicing Physicians Need to Know When Evaluating Patients With Suspected Pulmonary Embolism. Ann Intern Med. 2017 Mar 07; 166(5):361-363.